[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-function-assessment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-function-assessment":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100649486","phase-4-hormone-therapy-effects-on-brain-heart-health-during-the-menopausal-transition-100649486",false,"NCT07732452","Hormone thERapy Effects on BRAin-HEART Health During the Menopausal Transition","HER BRAVE HEART Trial - Hormone thERapy Effects on BRAin-HEART Health During the Menopausal Transition: A Randomized Feasibility Study","HERBRAVEHEART","Inclusion Criteria:\n\n* Women aged ≥ 45 years.\n* Perimenopausal or postmenopausal, defined as at least one of the following:\n\n  * Perimenopause, defined as menstrual cycle irregularity (changes in cycle length, skipped cycles, or amenorrhea ≥ 60 days) accompanied by vasomotor symptoms consistent with the menopausal transition.\n  * Postmenopause, defined as at least one of:\n\n    * ≥ 12 months of spontaneous amenorrhea, or\n    * bilateral oophorectomy, or\n    * hysterectomy with FSH \\> 40 IU\u002FL when menstrual history is unavailable.\n* Vasomotor symptoms with a negative impact on quality of life, defined as :\n\n  * Recurrent hot flashes (sudden sensations of heat, typically involving the face, neck, or chest, often associated with flushing and\u002For sweating), and\u002For\n  * Night sweats (episodes of excessive sweating during sleep), With associated interference in daily functioning, sleep, or overall quality of life, such that the participant would be an appropriate candidate for systemic menopausal hormone therapy in clinical practice.\n* Presence of at least one cardiovascular risk factor, defined as either:\n\n  * Hypertension (diagnosed hypertension, use of antihypertensive medication, or blood pressure ≥ 140\u002F90 mmHg on screening).\n  * Dyslipidemia (diagnosed dyslipidemia, use of lipid-lowering therapy, LDL ≥ 3.0 mmol\u002FL, or total cholesterol ≥ 5.2 mmol\u002FL).\n  * Type 2 diabetes mellitus, defined as HbA1c ≥ 6.5%, fasting plasma glucose ≥ 7.0 mmol\u002FL, or use of glucose-lowering medication.\n  * Obesity (body mass index ≥ 30 kg\u002Fm²).\n  * Current smoking.\n  * First-degree family history of premature cardiovascular disease, defined as myocardial infarction, stroke, or documented coronary artery disease occurring before age 55 years in a male relative or before age 65 years in a female relative.\n* Eligible for systemic MHT (i.e., no formal contraindication to MHT).\n* Able and willing to undergo research CMR and attend the 12-month follow-up assessment.\n* Able to provide written informed consent.\n* Not currently using systemic MHT at baseline, or willing to discontinue systemic MHT prior to randomization and remain off systemic MHT until allocation and baseline assessments are complete.\n\nExclusion Criteria:\n\n* Prior cardiovascular event or established cardiovascular disease, including myocardial infarction, stroke or TIA, coronary artery disease, heart failure, cardiomyopathy, or clinically significant valvular heart disease.\n* Uncontrolled hypertension or other unstable cardiovascular condition (e.g., unstable angina, decompensated heart failure, uncontrolled arrhythmia).\n* Formal contraindication to systemic menopausal hormone therapy, including estrogen-dependent cancer, unexplained vaginal bleeding, active severe liver disease, severe thrombophilia, antiphospholipid syndrome, prior or active VTE.\n* Standard contraindications to MRI (e.g., MRI-incompatible pacemakers or intracardiac devices, certain metallic implants, metallic foreign bodies in the eye, or severe claustrophobia not manageable).\n* Pregnant.\n* Active cancer on ongoing cardiotoxic chemotherapy.\n* Current use of systemic hormonal therapy outside the study strategy, including systemic menopausal hormone therapy, combined hormonal contraception, or systemic progestin-only contraception, with unwillingness or inability to discontinue prior to baseline and randomization.\n* Ten years or more since menopause, defined as ≥10 years from the final menstrual period or from bilateral oophorectomy\n* Participants currently using combined hormonal contraception or systemic progestin-only contraception who are willing to discontinue must complete a washout period of at least 4 weeks prior to the baseline visit and randomization","FEMALE","45 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn whether it is feasible to conduct a larger study comparing transdermal menopausal hormone therapy (MHT) versus no hormone therapy in menopausal women with vasomotor symptoms (hot flashes and night sweats) and at least one cardiovascular risk factor. The main questions it aims to answer are:\n\n* What proportion of eligible women agree to be randomly assigned to either receive MHT or not?\n* How many participants complete the 12-month follow-up, including repeat heart imaging?\n* Does transdermal MHT affect early changes in heart muscle tissue as measured by cardiac MRI?\n\nResearchers will compare immediate initiation of transdermal estradiol (a skin gel or patch) to a no-hormone therapy strategy to see if MHT influences early cardiovascular and brain-vascular changes over 12 months.\n\nParticipants will:\n\n* Be randomly assigned to start transdermal MHT within 2 weeks, or to use no hormone therapy for at least the first 3 months\n* Undergo a cardiac MRI and retinal eye imaging at the start of the study and again at 12 months\n* Complete cognitive testing and questionnaires about symptoms, sleep, and stress at both visits\n* Provide a blood sample for storage and future analysis of heart and brain health markers\n* Receive follow-up phone calls at 3, 6, and 9 months to review symptoms, medications, and any health changes",[27,28,29,30,31,32,33,34,35],"Menopause","Perimenopause","Vasomotor Symptoms","Cardiovascular Disease Risk Factor","Menopausal Hormone Therapy","Cardiac Remodeling","Myocardial Fibrosis","Microvascular Dysfunction","Cognitive Function Assessment","NOT_YET_RECRUITING","2026-07-23",{"date":39,"type":40},"2026-07-29","ACTUAL",{"date":42,"type":21},"2026-11",{"date":44,"type":21},"2029-01",{"name":46,"class":47},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100632252","prediction-of-cognitive-test-performance-using-ai-based-analysis-of-narrative-speech-100632252","NCT07511270","Prediction of Cognitive Test Performance Using AI-Based Analysis of Narrative Speech","Inclusion Criteria:\n\n1. Age 50 years or older\n2. Able to communicate verbally and understand study instructions\n3. Able to hear and speak clearly\n4. Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n1. Severe speech or hearing impairment\n2. History of major psychiatric disorders\n3. History of stroke, traumatic brain injury, Parkinson's disease, epilepsy, or other neurodegenerative diseases\n4. Current use of medications that may affect cognitive performance\n5. Unable to complete the study procedures due to severe attention deficits or agitation",true,"ALL","50 Years",{"count":58,"type":21},150,[60],"NA","This study aims to evaluate a new artificial intelligence (AI)-based method for measuring cognitive function using speech recordings. Participants will complete a short storytelling task in which they describe a story based on an image while their voice is recorded using a computer or mobile device.\n\nThe speech recordings will be analyzed using AI technology to identify patterns in speech that may be related to cognitive function. The system will then estimate scores that correspond to commonly used cognitive tests.\n\nTo evaluate the accuracy of this method, the AI-generated scores will be compared with results from standard cognitive assessments administered by trained researchers. These assessments may include tests commonly used to measure memory, attention, and other cognitive abilities.\n\nThe goal of this study is to determine whether speech analysis using AI can provide a convenient and efficient approach for cognitive assessment. If successful, this technology may help support early detection of cognitive decline and provide a practical tool for large-scale or remote cognitive screening.",[35,63,64],"Mild Cognitive Impairment","Subjective Cognitive Decline",[66,67,68,69,70,63],"Artificial Intelligence","Speech Biomarkers","Storytelling Task","Cognitive Screening","Voice Analysis","RECRUITING","2026-03-30",{"date":74,"type":40},"2026-04-06",{"date":76,"type":40},"2025-12-01",{"date":78,"type":21},"2026-04-30",{"name":80,"class":47},"Chang Gung Memorial Hospital",1]